tiprankstipranks
Advertisement
Advertisement

DNLI Stock Latest News

Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside
Company AnnouncementsDenali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside
4h ago
DNLI
Denali Therapeutics’ AVLAYAH Launch Reshapes Earnings Story
PremiumCompany Announcements
Denali Therapeutics’ AVLAYAH Launch Reshapes Earnings Story
21h ago
DNLI
Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on Denali Therapeutics as AVLAYAH Launch Gains Traction and Alzheimer’s Pipeline Advances; $42 Price Target Maintained
13d ago
DNLI
Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley
PremiumThe Fly
Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley
13d ago
DNLI
Denali Therapeutics price target raised to $34 from $25 at UBS
PremiumThe Fly
Denali Therapeutics price target raised to $34 from $25 at UBS
13d ago
DNLI
Denali Therapeutics price target raised to $34 from $31 at Baird
PremiumThe FlyDenali Therapeutics price target raised to $34 from $31 at Baird
13d ago
DNLI
Denali Therapeutics reports Q2 EPS (68c), consensus (47c)
Premium
The Fly
Denali Therapeutics reports Q2 EPS (68c), consensus (47c)
14d ago
DNLI
Denali Therapeutics treatment of frontotemporal dementia granted orphan status
Premium
The Fly
Denali Therapeutics treatment of frontotemporal dementia granted orphan status
17d ago
DNLI
Denali Therapeutics Sells Priority Review Voucher for Capital
PremiumCompany Announcements
Denali Therapeutics Sells Priority Review Voucher for Capital
23d ago
8K
DNLI
Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley
PremiumThe Fly
Denali Therapeutics price target raised to $36 from $35 at Morgan Stanley
28d ago
DNLI
Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank
PremiumThe Fly
Denali Therapeutics price target raised to $35 from $31 at Deutsche Bank
1M ago
DNLI
Denali Therapeutics falls -14.1%
PremiumThe Fly
Denali Therapeutics falls -14.1%
1M ago
DNLI
Denali Therapeutics falls -12.4%
PremiumThe FlyDenali Therapeutics falls -12.4%
1M ago
DNLI
Denali Therapeutics price target raised to $26 from $20 at Wedbush
Premium
The Fly
Denali Therapeutics price target raised to $26 from $20 at Wedbush
1M ago
DNLI
Denali Therapeutics resumed with an Overweight at JPMorgan
Premium
The Fly
Denali Therapeutics resumed with an Overweight at JPMorgan
1M ago
DNLI
Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
PremiumCompany Announcements
Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
2M ago
DNLI
Denali Monetizes FDA Voucher to Advance CNS Pipeline
PremiumCompany Announcements
Denali Monetizes FDA Voucher to Advance CNS Pipeline
2M ago
8K
DNLI
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
PremiumThe Fly
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
2M ago
DNLI
Denali Therapeutics Shareholders Back Board, Auditors, Executive Pay
PremiumCompany Announcements
Denali Therapeutics Shareholders Back Board, Auditors, Executive Pay
3M ago
8K
DNLI
Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors
PremiumCompany AnnouncementsBiogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors
3M ago
BIIB
DNLI
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
Premium
The Fly
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
3M ago
DNLI
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
Premium
The Fly
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
3M ago
DNLI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >